O

OMass Therapeutics

Biotech & Life Sciences · Oxford, United Kingdom · Founded 2016

OMass Therapeutics is a private biotechnology company focused on the discovery and development of small molecule drugs against inadequately drugged or intractable targets. The company's proprietary drug discovery platform, OdyssION, integrates novel biochemistry techniques, native mass spectrometry, and custom chemistry to study how a protein interacts with its native ecosystem. This approach allows for the identification of drug candidates that can modulate the activity of these targets. OMass is building a pipeline of small molecule therapeutics in the areas of rare diseases and immunology. The company's pipeline targets solute carriers, complex-bound proteins, and G protein-coupled receptors (GPCRs). The company's business model is to leverage its platform to develop a portfolio of drug candidates and then to partner with larger pharmaceutical companies for later-stage development and commercialization. OMass has raised significant capital to advance its pipeline, including a $100 million Series B financing. Keywords: drug discovery, small molecules, rare diseases, immunology, mass spectrometry, GPCRs, solute carriers, therapeutics, biotechnology, pharmaceutical